Unichem Laboratories rose 3.40% to Rs 154.95 after the company announced the receipt of ANDA approval for Buspirone Hydrochloride Tablets USP from the USFDA.
Unichem Laboratories announced that it has received ANDA approval for its Buspirone Hydrochloride Tablets USP, 5 mg, 10 mg, 15 mg, and 30 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Bristol-Myers Squibb Company (BMS), Buspar Tablets, 5 mg, 10 mg, 15 mg, and 30 mg.
Buspirone Hydrochloride Tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. The product will be commercialized from Unichem's Ghaziabad Plant.
Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
